A detailed history of Nisa Investment Advisors, LLC transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 110 shares of TBPH stock, worth $1,041. This represents 0.0% of its overall portfolio holdings.

Number of Shares
110
Previous 106 3.77%
Holding current value
$1,041
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$7.66 - $10.25 $30 - $41
4 Added 3.77%
110 $0
Q2 2024

Jul 19, 2024

SELL
$8.29 - $9.92 $132 - $158
-16 Reduced 13.11%
106 $0
Q1 2024

May 01, 2024

BUY
$8.22 - $11.59 $674 - $950
82 Added 205.0%
122 $1,000
Q3 2023

Nov 02, 2023

SELL
$8.38 - $10.44 $234 - $292
-28 Reduced 41.18%
40 $0
Q3 2022

Nov 07, 2022

BUY
$8.39 - $10.22 $570 - $694
68 New
68 $1,000
Q4 2021

Feb 03, 2022

SELL
$7.42 - $11.05 $51,940 - $77,350
-7,000 Closed
0 $0
Q3 2021

Oct 18, 2021

BUY
$6.77 - $14.41 $47,390 - $100,870
7,000 New
7,000 $52,000
Q2 2021

Aug 06, 2021

SELL
$14.52 - $22.46 $55,176 - $85,348
-3,800 Closed
0 $0
Q4 2020

Jan 25, 2021

BUY
$14.89 - $20.16 $1,682 - $2,278
113 Added 3.06%
3,800 $68,000
Q3 2020

Oct 20, 2020

BUY
$14.79 - $22.49 $48,023 - $73,025
3,247 Added 737.95%
3,687 $55,000
Q2 2020

Jul 27, 2020

SELL
$20.64 - $30.69 $99,278 - $147,618
-4,810 Reduced 91.62%
440 $9,000
Q1 2020

Apr 17, 2020

SELL
$17.84 - $31.21 $2,854 - $4,993
-160 Reduced 2.96%
5,250 $121,000
Q4 2019

Jan 17, 2020

SELL
$16.12 - $25.89 $49,810 - $80,000
-3,090 Reduced 36.35%
5,410 $140,000
Q3 2019

Oct 17, 2019

SELL
$16.51 - $23.78 $44,560 - $64,182
-2,699 Reduced 24.1%
8,500 $166,000
Q1 2019

Apr 17, 2019

BUY
$22.57 - $28.15 $252,761 - $315,251
11,199 New
11,199 $254,000

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $632M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.